Navigation Links
Regulus Reports Third Quarter 2013 Financial Results and Recent Highlights
Date:11/13/2013

60; Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  These and other risks concerning Regulus' financial position and programs are described in additional detail in Regulus' SEC filings.  All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

 Regulus Therapeutics Inc.Selected Financial InformationCondensed Statement of Operations(In thousands, except share and per share data)Three months endedSeptember 30,Nine months endedSeptember 30,2013201220132012(Unaudited)Revenues:Revenue under strategic alliances$

6,118$

2,809$

14,115$

9,462Total revenues6,1182,80914,1159,462Operating expenses:Research and development7,1065,24821,71014,735General and administrative1,9171,0935,5452,998Total operating expenses9,0236,34127,25517,733Loss from operations(2,905)(3,532)(13,140)(8,271)Other income (expense), net736(2,159)(3,605)(2,289)Loss before income taxes(2,169)(5,691)(16,745)(10,560)Income tax (benefit) expense(5)(6)(4)(28)Net loss$

(2,164)$

(5,685)$

(16,741)$

(10,532)Net loss per share:Basic$

(0.05)$

(15.98)$

(0.45)$

(41.03)Diluted$

(0.07)$

(15.98)$

(0.45)$

(41.03)Weighted average shares used to compute net loss per share:Basic40,154,812355,73537,367,368256,682Diluted41,555,660355,73537,367,368256,682 Regulus Therapeutics Inc.Condensed Bala
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Regulus Presents Positive Preclinical Data Demonstrating that microRNA-21 Plays an Important Role in Alport Syndrome
2. Regulus Announces Timing for Third Quarter 2013 Financial Results Webcast and Conference Call
3. Regulus Announces Significant Progress in Strategic Alliance with AstraZeneca and Selection of a New Pre-Clinically Validated microRNA Oncology Target
4. Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights
5. Regulus Announces Timing for Second Quarter 2013 Financial Results Webcast and Conference Call
6. Regulus Names Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors
7. Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference
8. Regulus Provides Update on Road to the Clinic Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights
9. Regulus Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
10. Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
11. Regulus to Present at Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , South Korea, July 2, 2015 ALPINION ... a new E-CUBE Series ultrasound system. Developed to enhance ... clinical areas, the E-CUBE 15 EX produces superb image ... clinical performance in women,s health, general imaging, and shared ... The latest in the renowned E-CUBE Series, the ...
(Date:7/2/2015)... July 2, 2015   Wilson Therapeutics AB , ... Hans Schikan to its board of directors. The appointment ... Meeting on June 30. "We are delighted ... Jonas Hansson , CEO of Wilson Therapeutics. "Hans ... we look forward to his contributions to the Company." ...
(Date:7/1/2015)... July 1, 2015   Cochlear Limited ... solutions, announced today the US Food and Drug ... Implant with Slim Straight Electrode (CI522). Built on ... close collaboration with the world,s leading surgeons, the ... designed to provide the most discreet appearance for ...
Breaking Medicine Technology:E-CUBE 15 EX from ALPINION Enhances User Experience and Patient Care 2E-CUBE 15 EX from ALPINION Enhances User Experience and Patient Care 3Wilson Therapeutics Appoints Hans Schikan to its Board of Directors 2Cochlear Combines the World's Thinnest Cochlear Implant Platform with the Industry's Thinnest Full Length Electrode 2Cochlear Combines the World's Thinnest Cochlear Implant Platform with the Industry's Thinnest Full Length Electrode 3
... FAIRFIELD, N.J., Jan. 28, 2011 The Healthcare ... of the Year" is Freda Lewis-Hall, MD, chief medical ... Dr. Lewis-Hall has held leadership roles in direct ... (Photo: http://photos.prnewswire.com/prnh/20110128/DC38263 ) ...
... 2011 TechniScan (OTC Bulletin Board: TSNI ... and commercialization of an automated 3D breast ultrasound imaging ... will present at RetailInvestorConferences.com. DATE: , February 3rd, ... This will be a live, interactive online event where ...
Cached Medicine Technology:Pfizer Chief Medical Officer Freda Lewis-Hall Named 2011 Woman of the Year by The Healthcare Businesswomen's Association 2Pfizer Chief Medical Officer Freda Lewis-Hall Named 2011 Woman of the Year by The Healthcare Businesswomen's Association 3Pfizer Chief Medical Officer Freda Lewis-Hall Named 2011 Woman of the Year by The Healthcare Businesswomen's Association 4TechniScan to Present Live, Online at RetailInvestorConferences.com on February 3rd 2
(Date:7/2/2015)... ... July 02, 2015 , ... Scientists at ... nearly $4 million through five federal grants to study a group of related ... deadly diseases. , The research will be conducted in the Regional Biocontainment ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... healthcare providers, has been retained to lead a national chief operating officer ... executive search firms in the healthcare industry, B. E. Smith has recently placed ...
(Date:7/2/2015)... ... July 02, 2015 , ... Evolved Ayurvedic Discoveries , ... an intention to partner with companies that share a similar mission of providing ... water soluble, Cannabidiol (CBD) formulations, combined with Ayurvedic herbs, are now available for ...
(Date:7/2/2015)... ... ... A team of quality control (QC) experts at GE Healthcare, led by ... enhanced workflow. Now, Dr. Dunne’s lab has set a lofty goal: to become the ... network. , Join the team members for a new, free educational webinar ...
(Date:7/2/2015)... ... July 02, 2015 , ... Cs &A, the ... Timing announced the release and publication of their newest offering to complement the ... and Newsletter. , Designed in support of coverage for the full spectrum ...
Breaking Medicine News(10 mins):Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 2Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 3Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 4Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 2Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 3Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 2Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 3Health News:GE Healthcare Webinar Spotlights GE’s Own, Internal QC Lab Enhancements with Six Sigma 2Health News:GE Healthcare Webinar Spotlights GE’s Own, Internal QC Lab Enhancements with Six Sigma 3Health News:Cs &A Releases the SEMI TIMING Newsletter Specific to the Semiconductor Timing Industry 2Health News:Cs &A Releases the SEMI TIMING Newsletter Specific to the Semiconductor Timing Industry 3Health News:Cs &A Releases the SEMI TIMING Newsletter Specific to the Semiconductor Timing Industry 4
... in blood pressure, disease scores , , SUNDAY, March 30 ... electronically, good doctor-patient communication helps reduce the risk of ... study. , The four-year study included rural and urban ... were otherwise healthy. They were divided into two groups, ...
... agent that combines 2 medications , , SUNDAY, March 30 (HealthDay ... to make sense of a trial showing that a drug ... no apparent benefit to people at high risk of heart ... a well-known statin -- simvastatin -- with ezetimibe, which also ...
... In a comparison of anticoagulants and stents for use ... and tirofiban had similar outcomes for some cardiac measures ... received stents that released the drug sirolimus had a ... months than patients who received uncoated stents, according to ...
... restenosis risk and don,t increase mortality probability , , SUNDAY, ... tubing placed in diseased coronary arteries to keep them ... attack patients, new research shows. , In the largest ... -- the drug in question retards the growth of ...
... RN ... Organization, HOUSTON, March 29 ... a stronger voice to speak,out for patients and themselves, a northwest Houston ... bargaining,rights., RNs at Cypress Fairbanks Medical Center Hospital voted 119 to ...
... cancer deaths could be avoided with lifestyle changes, experts ... therapies that could cut cancer deaths in half. , ... recent American Cancer Society report that said as many ... with lifestyle changes, such as quitting smoking, maintaining a ...
Cached Medicine News:Health News:Combining Internet With Office Visits Cut Heart Attack Risks 2Health News:Cholesterol Drug Controversy Continues 2Health News:Cholesterol Drug Controversy Continues 3Health News:Comparison of anticoagulants for angioplasty show similar outcomes 2Health News:Drug-Eluting Stents Safe After Heart Attack 2Health News:First Unionized Hospital in Texas 2Health News:First Unionized Hospital in Texas 3Health News:You May Be the Key to Cancer Prevention 2Health News:You May Be the Key to Cancer Prevention 3
... AT20R places fast and accurate ... fingertips. Utilising standard computer hardware ... environment with new testing and ... easily integrated into a modern ...
... a test capability extending to 80, the ... patient's visual field, allowing peripheral defects that ... to be explored. Practice Management Integration provides ... With the Medmont Studio package the practitioner ...
... SNPstream Genotyping System provides an automated scalable ... over 800,000 SNP genotypes per day. Combined ... flexibility, this enables you to process a ... robust solution designed to deliver your intended ...
Egg-Shaped Bioceramic orbital implants insert easily into orbital socket and will not cling to surrounding tissue. Improved interconnectivity between pores enhances vascularization. Implants may be e...
Medicine Products: